✦ LIBER ✦

Dynamics of lamivudine-resistant mutants (YMDD mutations) development during long-term therapy for chronic hepatitis B

✍ Scribed by F. van Bommel; T. Wunsche; T. Kaul; A. Schernick; M. Pascu; B. Wiedenmann; U. Hopf; T. Berg

Book ID: 117372750
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 162 KB
Volume: 38
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(03)80881-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is it safe to stop lamivudine after the

Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B?

✍ V.W.S. Wong; H.L.Y. Chan; M.L. Wong; Nancy Leung 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 97 KB

Clearance of the original hepatitis B vi

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

✍ Chau-Ting Yeh; Rong-Nan Chien; Chia-Ming Chu; Yun-Fan Liaw 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB

Dynamic quasispecies analysis of YMDD mu

Dynamic quasispecies analysis of YMDD mutants in patients with chronic hepatitis B resistant to lamivudine

✍ L. Castera; C. Pallier; A. Soulier; D. Dhumeaux; J.M. Metreau; J.M. Pawlotsky 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Emergence of YMDD motif mutant of hepati

Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea

✍ Yong Han Paik; Hyo Young Chung; Wang-Shick Ryu; Kwan Sik Lee; Ji Sook Lee; Jung 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 272 KB

Interferon for treatment of breakthrough

Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy

✍ Fumitaka Suzuki; Akihito Tsubota; Norio Akuta; Takashi Someya; Masahiro Kobayash 📂 Article 📅 2002 🏛 Springer Japan 🌐 English ⚖ 265 KB

Severe acute exacerbation of liver disea

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B

✍ Akihito Tsubota; Yasuji Arase; Fumitaka Suzuki; Mariko Kobayashi; Marie Matsuda; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract The pretherapy factors that could influence the emergence of resistant hepatitis B virus (HBV) tyrosine‐methionine‐aspartate‐aspartate (YMDD) motif mutants against lamivudine are not fully known in prolonged lamivudine therapy for hepatitis B e antigen (HBeAg)‐positive chronic hepatitis